Free Trial
NASDAQ:PRTG

Portage Biotech Q4 2024 Earnings Report

Portage Biotech logo
$7.63 +0.67 (+9.63%)
Closing price 09/3/2025
Extended Trading
$7.63 0.00 (0.00%)
As of 09/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Portage Biotech EPS Results

Actual EPS
-$24.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Portage Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Portage Biotech Announcement Details

Quarter
Q4 2024
Time
N/A
Conference Call Date
Thursday, August 15, 2024
Conference Call Time
8:00AM ET

Earnings Documents

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Portage Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Portage Biotech and other key companies, straight to your email.

About Portage Biotech

Portage Biotech (NASDAQ:PRTG) (NASDAQ: PRTG) is a clinical‐stage biotechnology company focused on building a diversified portfolio of innovative therapeutics targeting rare diseases and oncology indications. Leveraging an asset‐centric business model, Portage Biotech acquires and in‐licenses development‐stage compounds from academic institutions and biotechnology partners, then advances these assets through preclinical studies and early‐stage clinical trials within dedicated subsidiary entities.

The company’s pipeline spans small molecules, biologics and cell therapies, with programs directed at conditions such as myeloproliferative disorders, inherited blood disorders and solid tumor oncology. By organizing each development program under a stand‐alone subsidiary, Portage Biotech centralizes shared functions—such as regulatory affairs, manufacturing and clinical operations—while allowing focused teams to drive individual assets toward key value‐creating milestones.

Headquartered in New York, Portage Biotech maintains collaborations with research institutions in North America and Europe to expand its discovery footprint and accelerate candidate selection. The company’s management team brings experience from established biopharmaceutical and venture‐backed organizations, supporting a strategy of disciplined capital allocation and milestone‐driven advancement.

Portage Biotech’s approach aims to unlock value in early‐stage projects through targeted partnerships and efficient resource deployment, positioning the company to out‐license or co‐develop programs as they progress toward pivotal clinical readouts.

View Portage Biotech Profile

More Earnings Resources from MarketBeat